ACTRN12622000280707RecruitingPhase 1
se of the Nutromics Sensor Device for the quantification of clinical targets to evaluate the safety of the Nutromics Sensor Device and to determine vancomycin concentrations in interstitial fluid using the Nutromics Sensor Device in healthy adults.
utromics IP Pty Ltd0 sites27 target enrollmentStarted: February 15, 2022Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Enrollment
- 27
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Non-randomised trial
- Primary Purpose
- Treatment
Eligibility Criteria
- Ages
- 18 Years to 60 Years (—)
- Sex
- All
Inclusion Criteria
- •Age 18-60 years.
- •-Individuals without clinically significant medical abnormalities contraindicating participation as determined by Study Investigators, including, but not limited to:
- •a) Physical examination without any clinically relevant findings.
- •b) Systolic blood pressure in the range of 90 to 140 mmHg (inclusive) and diastolic blood pressure in the range of 50 to 90 mmHg (inclusive) after 5 minutes of rest in a supine position.
- •c) Pulse rate in the range of 60 to 100 bpm (inclusive) after 5 minutes of rest in a supine position. A 40-60 bpm (inclusive) may be considered acceptable for participants without clinically significant findings at the discretion of the Principal Investigator.
- •d) Body temperature (tympanic), between 35.5°C and 37.5°C (inclusive).
- •e) No clinically significant findings in serum biochemistry and haematology tests, and urinalysis contraindicating participation as determined by Study Investigators.
- •Female participants with childbearing potential must from the period of signing the consent form until at least 28 days after the removal of the sensor:
- •a) Have a negative pregnancy test at Screening and Study Visits.
- •b) Not planning to become pregnant.
- •c) Not be breastfeeding.
- •d) Not donate ova.
- •If engaging in sexual intercourse, they are required to use effective contraception during the study and strongly recommended to use effective contraception for at least 28 days after the removal of the sensor.
- •- Allow for digitally captured images and recordings of the skin surface at the sensor application site while maintaining participant anonymity.
- •- Participation is not influenced by vaccination status. However, participants who have been vaccinated within one week of the Study visit will not be recruited.
- •- Willingness to provide written informed consent and comply with the study protocol.
Exclusion Criteria
- •Poor venous access for venepuncture
- •Participants who are currently receiving or have received any investigational drug/device within the last 30 days.
- •History of allergic reactions to vancomycin, metals, plastics and adhesives which, in the opinion of the Study Investigators, would increase the risk of having allergic reactions associated with skin allergies, vancomycin administration.
- •Active illnesses
- •Consumption of prescription medications except oral contraceptive pills.
- •Use of illicit drugs or alcohol consumption, which, in the opinion of the Study Investigators, may interfere with the completion of the study.
Investigators
Similar Trials
Completed
Not Applicable
Sensor for Measuring the blood glucose level as input for the ARtificial pancreas: a sensor validation Trial.Diabetes type 110018424NL-OMON49011Inreda Diabetic B.V.10
Active, not recruiting
Phase 1
The lactate in pregnancy studyISRCTN38095366niversity of Liverpool10
Completed
Not Applicable
SPLENDID I; Development of a sensor for the detection of eatingGeen aandoening-NL-OMON40888Wageningen Universiteit20
Recruiting
Not Applicable
Establishment of a measuring method for gastrointestinal tissue oxygenation to predict postoperative complications (Oxygen Saturation of Colon And Rectum)C20C18Malignant neoplasm of rectumMalignant neoplasm of colonDRKS00021398Klinik für Allgemeine, Viszeral-, Thorax-, Transplantations- und Kinderchirurgie UKSH Campus Kiel96
Completed
Not Applicable
Developement of an applicable tool for measuring nurses' musculoskeletal workload on inpatient wards in acute care clinicsM54M25.5M79.1M51M62M99DorsalgiaPain in jointMyalgiaOther intervertebral disc disordersOther disorders of muscleBiomechanical lesions, not elsewhere classifiedDRKS00014100Institut für Physiotherapie Universitätsklinikum Jena8